Overview

• The French government has officially restarted the medical cannabis legalization process by notifying the European Commission of regulatory texts defining its framework.
• The experimental program benefiting 1,200 patients has been extended until March 31, 2026, ensuring continued access during the transition period.
• Medical cannabis will be prescribed only when other treatments fail, with initial prescriptions required to be issued in a hospital setting.
• The Ministry of Health has requested an evaluation from the Haute Autorité de Santé to assess the therapeutic benefits of medical cannabis and determine potential reimbursement policies.
• The regulatory framework includes a renewable five-year authorization period, reflecting a cautious approach to balancing patient needs, scientific evidence, and regulatory oversight.